Prosecution Insights
Last updated: April 19, 2026
Application No. 17/179,931

COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS

Final Rejection §103
Filed
Feb 19, 2021
Examiner
BURKHART, MICHAEL D
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sixfold Bioscience Ltd.
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
3y 3m
To Grant
72%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allow Rate
507 granted / 811 resolved
+2.5% vs TC avg
Moderate +10% lift
Without
With
+9.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
45 currently pending
Career history
856
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 811 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 21-26, 29, 32-39 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shapiro et al (WO 2015/042101, of record, reference below is to the US patent publication of the WO document, US 2017/0121708, also of record) in view of Kim et al (Sci Rep. 2015, of record). Claims 21-26, 29-39 is/are rejected under 35 U.S.C. 103 as being unpatentable over Shapiro et al (WO 2015/042101, of record) in view of Kim et al (Sci Rep. 2015 of record) and Stephan et al (US PGPUB 2016/0145348, of record). These rejections are maintained for reasons made of record and for reasons set forth below. Response to Arguments Applicant's arguments filed 9/29/2025 have been fully considered but they are not persuasive. Applicants essentially assert that Shapiro et al is directed to RNA-DNA hybrids, not DNA nanoparticles as in the instant claims. Such is not convincing. The instant claims only require “DNA”, and do not remove RNA/DNA hybrids from the claimed scope Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Burkhart whose telephone number is (571)272-2915. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Michael Burkhart Examiner Art Unit 1633 /MICHAEL D BURKHART/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Feb 19, 2021
Application Filed
Mar 22, 2025
Non-Final Rejection — §103
Sep 29, 2025
Response Filed
Jan 10, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600796
NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
2y 5m to grant Granted Apr 14, 2026
Patent 12595460
Method and Apparatus for Producing CAR T Cells
2y 5m to grant Granted Apr 07, 2026
Patent 12590148
METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY
2y 5m to grant Granted Mar 31, 2026
Patent 12577546
PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
2y 5m to grant Granted Mar 17, 2026
Patent 12565675
METHOD FOR SELECTING APTAMERS WITH HIGH TARGET SPECIFICITY IN A MICROFLUIDIC DEVICE PLATFORM FOR CO-CULTURE OF MULTIPLE TISSUES
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
72%
With Interview (+9.9%)
3y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 811 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month